In CTONG0806 study [20], patients assigned to the chemotherapy arm (pemetrexed) experienced a statistically significant improvement in PFS (4.8 versus 1.6 months; HR, 0.54; 95% CI, 0.40–0.75; P < 0.001) and a trend toward improvement in OS (12.4 versus 9.6 months; HR, 0.72, 95% CI 0.49–1.04; P = 0.077) compared with gefitinib in second-line therapy for patients with advanced nonsquamous NSCLC harboring wild-type EGFR mutations (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.